Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array-based cytokine profiling

Therapy resistance remains a major obstacle in the treatment of solid tumors and accounts for most cancer-related deaths. While tumor-intrinsic mechanisms have been well-studied, the tumor microenvironment (TME) is now recognized as a major driver of resistance through non-genetic, cell-extrinsic signaling. Stromal and immune cells-including fibroblasts, macrophages, endothelial cells, and regulatory immune cells-interact with cancer cells via cytokine signaling, direct contact, and extracellular matrix (ECM) remodeling to promote survival, immune evasion, and therapeutic adaptation.

This review examines cytokine-mediated signaling mechanisms within the TME that contribute to resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy, drawing on studies with a specific focus on antibody array-based multiplex proteomic profiling.

Across multiple tumor types, molecular profiling studies have identified recurrent cytokine and growth factor signaling programs that drive therapy resistance through paracrine and autocrine mechanisms. Key pathways include IL-6/STAT3, CXCL12/CXCR4, and HGF/c-MET among others, through which stromal and immune cells support tumor survival, immune suppression, and therapy evasion. These findings demonstrate that cytokine-mediated resistance mechanisms differ across therapeutic modalities and cellular contexts. Clinical studies targeting these pathways further illustrate how biological context and pathway redundancy influence therapeutic response.

Cytokine-driven signaling within the TME plays a central role in therapy resistance. Protein profiling studies have contributed mechanistic insight into these interactions and helped define resistance-associated pathways across treatment settings. Ongoing clinical studies will determine how targeting these pathways can be most effectively applied to improve patient outcomes.